BIOMAT Database Logo BIOMAT Database Logo

[Experience with a l-dopa retard preparation in the peroral long-term therapy of the Parkinsonian syndrome]. 1976

H Binder, and F Gerstenbrand, and J Grünberger, and E Gründig, and H Schubert

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008134 Long-Term Care Care over an extended period, usually for a chronic condition or disability, requiring periodic, intermittent, or continuous care. Care, Long-Term,Long Term Care
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010302 Parkinson Disease, Secondary Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42) Atherosclerotic Parkinsonism,Secondary Parkinsonism,Symptomatic Parkinson Disease,Parkinson Disease, Secondary Vascular,Parkinson Disease, Symptomatic,Parkinsonism, Secondary,Parkinsonism, Symptomatic,Secondary Vascular Parkinson Disease,Parkinsonism, Atherosclerotic,Secondary Parkinson Disease,Symptomatic Parkinsonism
D010552 Personality Assessment The determination and evaluation of personality attributes by interviews, observations, tests, or scales. Articles concerning personality measurement are considered to be within scope of this term. Assessment, Personality,Assessments, Personality,Personality Assessments
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females

Related Publications

H Binder, and F Gerstenbrand, and J Grünberger, and E Gründig, and H Schubert
Apomorphine SC treatment in parkinsonian patients with long-term L-dopa syndrome during L-dopa drug holiday.
January 1995, Journal of neural transmission. Supplementum,
H Binder, and F Gerstenbrand, and J Grünberger, and E Gründig, and H Schubert
[Long-term therapy with a retard theophylline preparation].
May 1995, Fortschritte der Medizin,
H Binder, and F Gerstenbrand, and J Grünberger, and E Gründig, and H Schubert
[Long-term therapy of Parkinson's syndrome with L-dopa].
October 1979, ZFA. Zeitschrift fur Allgemeinmedizin,
H Binder, and F Gerstenbrand, and J Grünberger, and E Gründig, and H Schubert
[L-dopa with inhibitor in the treatment of parkinsonian syndrome-results of long-term observations].
January 1981, Neurologia i neurochirurgia polska,
H Binder, and F Gerstenbrand, and J Grünberger, and E Gründig, and H Schubert
Delayed onset of responses to single doses of L-dopa in parkinsonian fluctuators on long-term L-dopa therapy.
January 1986, Clinical neuropharmacology,
H Binder, and F Gerstenbrand, and J Grünberger, and E Gründig, and H Schubert
[Clinical significance of long-term treatment of L-dopa with bromocriptine in parkinsonian patients who showed declining efficacy during L-dopa therapy].
March 1985, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
H Binder, and F Gerstenbrand, and J Grünberger, and E Gründig, and H Schubert
[L-dopa therapy in Parkinsonian syndromes].
September 1970, Il Policlinico. Sezione pratica,
H Binder, and F Gerstenbrand, and J Grünberger, and E Gründig, and H Schubert
[L-dopa in the treatment of the Parkinsonian syndrome].
January 1973, Neurologia, psihiatria, neurochirurgia,
H Binder, and F Gerstenbrand, and J Grünberger, and E Gründig, and H Schubert
[Modalities of treatment of Parkinsonian syndrome with L-dopa].
January 1972, International journal of neurology,
H Binder, and F Gerstenbrand, and J Grünberger, and E Gründig, and H Schubert
[Treatment of the parkinsonian syndrome with L-dopa and amantadine].
January 1973, Neurologia, psihiatria, neurochirurgia,
Copied contents to your clipboard!